Related Experiment Videos
Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b
P Bramanti1, E Sessa, C Rifici
1Centro per lo Studio ed il Trattamento dei Neurolesi Lungodegenti, Cattedra di Neurofisiopatologia, University of Messina, Italy.
Neurology
|December 17, 1998
Summary
Interferon beta-1b (IFNbeta-1b) treatment may worsen spasticity in patients with multiple sclerosis (MS). Further research is essential before widespread use in primary progressive MS patients.
Area of Science:
- Neuroimmunology
- Neurology
- Multiple Sclerosis Research
Background:
- Spasticity is a common and disabling symptom in multiple sclerosis (MS).
- Interferon beta-1b (IFNbeta-1b) is a treatment used for MS, but its effects on spasticity are not fully understood.
Purpose of the Study:
- To investigate the effect of interferon beta-1b (IFNbeta-1b) treatment on spasticity in patients with primary progressive multiple sclerosis (PPMS).
Main Methods:
- A cohort of 19 patients with primary progressive MS received IFNbeta-1b treatment.
- A control group of 19 patients with primary progressive MS did not receive IFNbeta-1b treatment.
- Spasticity levels and antispasticity medication requirements were monitored.
Main Results:
- Thirteen out of 19 patients (68%) treated with IFNbeta-1b experienced an enhancement of spasticity.
- Patients with increased spasticity required higher doses of antispasticity medications.
Conclusions:
- Interferon beta-1b (IFNbeta-1b) treatment may exacerbate spasticity in primary progressive MS patients.
- The findings suggest caution regarding the widespread use of interferons in this patient population.
- Further studies are warranted to clarify the risks and benefits of IFNbeta-1b in PPMS.